Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
54 NC counties and 1 VA county are under alert, including Wake, Cumberland, Durham, Johnston, and Orange counties.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,051.03
+0.17 (+0.02%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
37
38
Next >
BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC
March 08, 2022
BioNTech SE (NASDAQ: BNTX) has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to its FixVac candidate BNT116...
Via
Benzinga
WHO Conditionally Recommends Merck's COVID-19 Antiviral Pill For High-Risk Patients
March 03, 2022
A World Health Organization (WHO) panel has backed the use of Merck & Co Inc's (NYSE: MRK) COVID-19 antiviral pill for high-risk patients. The expert...
Via
Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
March 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...
Via
Benzinga
Intellia Shares Updated Data On Gene Editing Durability In Rare Disease
March 01, 2022
Eight months after delivering promising biomarker data from one of the first CRISPR trials, Intellia Therapeutics Inc (NASDAQ: NTLA) presented additional data...
Via
Benzinga
Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test
February 28, 2022
Intellia Therapeutics said its gene-editing drug lowered levels of a troublesome protein.
Via
Investor's Business Daily
Does the FDA Rollback Of Regeneron And Eli Lilly COVID Treatment EUAs Signal A Need To Look Beyond Monoclonal Antibodies? NanoViricides, Inc. Looks To Meet This Need With A New Approach
February 28, 2022
Photo credit: Marcelo Leal and Kate Hliznitsova on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended...
Via
Benzinga
3 Moonshot Stocks Insiders Are Buying. What Do They Know?
February 25, 2022
Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. These three all offer that enticing feature.
Via
InvestorPlace
7 Low Volatility Stocks to Buy Right Now for Steady Returns
February 24, 2022
A great way to find low volatility stocks is to look for a beta that's less than 1.0. Here are seven to buy as market turbulence increases.
Via
InvestorPlace
KOD Stock Alert: Why Is Kodiak Sciences Plunging 80% Today?
February 23, 2022
Disappointing drug trial results have sent Kodiak Sciences and shares of KOD stock plunging more than 80% in today's trading session.
Via
InvestorPlace
S&P 500 Slips Further into Correction Territory as Stocks Give Up Gains
February 23, 2022
Stocks have pulled back from this morning's gains, amid the ongoing Russia-Ukraine border crisis, with all three benchmarks looking to extend their losing streaks.
Via
Talk Markets
Kodiak Stock Pummeled After Attempt To Improve On Regeneron's Blockbuster Backfired
February 23, 2022
Kodiak hoped a less frequent dosing plan would benefit patients with an eye disease.
Via
Investor's Business Daily
Why Kodiak Sciences Shares Are Plunging Today
February 23, 2022
Kodiak Sciences Inc (NASDAQ: KOD) has announced topline results from its Phase 2b/3 trial evaluating KSI-301 in treatment-naïve subjects with neovascular (wet) age-...
Via
Benzinga
Is Moderna the Next Gilead or the Next Regeneron?
February 22, 2022
MRNA stock is seen purely as a Covid-19 play. Until Moderna can prove it's not a one-hit wonder, shares are likely to remain depressed.
Via
InvestorPlace
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
February 18, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO...
Via
Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial
February 18, 2022
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab...
Via
Benzinga
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
February 17, 2022
Can the formerly red-hot biotech segment return to its previous glory?
Via
Investor's Business Daily
Biotech Travere Therapeutics Stock Earns Relative Strength Rating Upgrade
February 14, 2022
Travere shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
Large Cap Biopharma- Well Positioned For Choppy Markets
February 14, 2022
If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets.
Via
Talk Markets
5 Value Stocks To Watch In The Healthcare Sector
February 14, 2022
What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be...
Via
Benzinga
Lilly's Antibody Receives FDA Emergency Use Nod For Mild-To-Moderate COVID-19
February 14, 2022
The FDA on Friday authorized Eli Lilly And Co's (NYSE: LLY) COVID-19 antibody drug for people aged 12 and older at risk of severe illness. The FDA authorized...
Via
Benzinga
Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes
February 11, 2022
Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels.
Via
Investor's Business Daily
Alnylam Clocks 76% Increase In Q4 Product Sales, Expects FY22 Product Sales Of Up To $1B
February 10, 2022
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY)
Via
Benzinga
Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis
February 10, 2022
The
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
February 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
10 Biggest Price Target Changes For Tuesday
February 08, 2022
Keybanc raised Take-Two Interactive Software, Inc. (NASDAQ: TTWO) price target from $185 to $190. Take-Two Interactive shares fell 2.8% to $170.21 in pre-market trading.
Via
Benzinga
Pacira Pharmaceuticals Stock Scores A Healthy 79 Relative Strength Rating
February 07, 2022
The Relative Strength (RS) Rating for Pacira Pharmaceuticals moved up into a new percentile Monday, as it got a small lift to 79.
Via
Investor's Business Daily
Cathie Wood's Ark Invest Sheds Stake In This Large-Cap Pharma Ahead Of Earnings
February 05, 2022
Big pharma reporting season was muted, with the quarterly results and guidance coming in mixed.
Via
Benzinga
Stock Market Rally Volatile; Google, Facebook, Amazon, Snap Are Earnings Movers: Weekly Review
February 04, 2022
The major indexes slashed weekly gains after Monday's follow-through day.
Via
Investor's Business Daily
Regeneron Scores Quarterly Beat On Covid Cocktail — But Future Sales Are Shaky
February 04, 2022
Regeneron posted 104% sales growth, including $2.3 billion from REGEN-COV.
Via
Investor's Business Daily
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
37
38
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.